Molecure and Ocean Biomedical (OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors Oct 15, 2024 07:36AM
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibito Oct 15, 2024 07:30AM
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now Oct 31, 2023 07:00AM